from Mike Havrilla: The major risk factor for MACK includes expected failure for several Phase II clinical trials for MM-121 as previously reported and updated in the recent prospectus filing. I believe this is mostly a headline risk since most of the bad news should already be reflected in stock unless the drug fails in every ongoing Phase II trial.
This is a stock which needs little reason to get beat up any more, but it sounds like more reasons might be a comin'.....
Market Data 
Markets 
AI
